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Background:Chronic venous insufficiency (CVI) represents a social and health care problem because it affects working age
populations, particularly in jobs requiring orthostasis, has no effective pharmacologic treatment, and requires surgery.
Oxidative stress is present in varicose veins, but whether this is reflected in the plasma is controversial. We aimed to
quantify plasma oxidative stress biomarkers in the early stages of CVI and calculate a global index of oxidative stress
representative of the disease.
Methods: Plasma was obtained from blood samples of nine patients with CEAP C2 stage CVI and 10 healthy controls.
Biomarkers related to antioxidant defense systems (total thiols, reduced glutathione, uric acid, total antioxidant capacity,
catalase), oxidative damage (malondialdehyde-bound protein, protein carbonyls, advanced oxidation products, and
3-nitrotyrosine), and activity of enzymes producing key free radicals (xanthine oxidase and myeloperoxidase) were
assessed.
Results: Compared with the controls, CVI patients exhibited decreased catalase activity and thiol levels and increased
malondialdehyde-bound protein and protein carbonyls. These parameters were used to calculate the global index of
oxidative stress in CVI, which was significantly different between groups.
Conclusions: It is possible to detect significant changes in plasma oxidative stress biomarkers in early stages of CVI and to
calculate a global index representative of the oxidative status in an individual. This index, with the appropriate validation
in a larger population, could be used for early detection or progression of CVI. (J Vasc Surg 2013;57:205-13.)
Clinical Relevance: This report describes the calculation of a global index of oxidative status that allows detecting
differences at early stages of chronic venous insufficiency (CVI). We propose that this index can be used as a diagnostic
tool for early detection of CVI or its progression. Obviously, this requires further development and studies, including a
larger number of individuals, which is a limitation of this study; for example, to include patients at C1 stages of CVI, who
do not exhibit varicose veins, and to monitor them in a longitudinal study to establish if an initial elevation of oxidative
stress can predict CVI progression. Although CVI is not a life-threatening condition, it is relatively common, particularly
in some risk groups, and surgery is the treatment of choice. Therefore, an early detection in groups at risk and the
development of preventive treatments with antioxidant-related pharmacologic therapy could reduce the number of
surgical interventions with all the inconveniences and cost implicated. Another possible application of this tool could be
to predict the progression of the disease; for example, screening patients undergoing surgery and assessing the possible
relationship between initial oxidative status and the development of recurrence.
q
a
T
e
o
r
c
v
c
c
v
s
s
w
d
m
mChronic venous insufficiency (CVI) is a disease of un-
known origin, associated with valvular incompetence, ve-
nous dilatation, blood stasis, hypertension, and hypoxia,
that manifests clinically with varicose veins.1 CVI is a com-
mon condition and has a wide distribution worldwide, with
the highest reported rates in industrialized countries.2,3
CVI is an important social and health problem that affects
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ssociated with orthostasis,2,4 contributing to job absence.
he pharmacologic treatments presently available are not
ffective, and surgery is the treatment of choice.
A large body of evidence has associated CVI with
xidative stress of the varicose vein wall.5-7 The source of
eactive oxygen species (ROS) is activated inflammatory
ells—circulating and infiltrated in the vein—as well as the
aricose vein wall itself.5 Eventually, the oxidative state
ontributes to the progression of valvular incompetence,
reating a vicious circle.7
Although oxidative stress is increased in the varicose
ein wall of patients with CVI, only a few controversial
tudies have investigated the levels of plasma oxidative
tress biomarkers.8,9 The determination of CVI biomarkers
ould be clinically desirable because it could be used for
iagnostic purposes and for the development of new phar-
acologic treatments. Plasma is a suitable fluid to measure
arkers of oxidative stress in CVI. Plasma is simple to
btain from a blood sample and reflects the global oxidative
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January 2013206 Condezo-Hoyos et alstress status of an individual because it contains the ROS
produced by the damaged venous tissue and by infiltrated
or circulating activated inflammatory cells.5-7,10
The studies that have measured oxidative stress bio-
markers in CVI have focused on individual parameters that
might have a large intraindividual and interindividual vari-
ability and yield conflicting results.8,9 Moreover, the com-
plex and multifactorial nature of oxidative stress makes it
difficult to assign a prevalent role in the pathology to a
particular marker. A recently developed global index or
score of oxidative stress status—the OXY-SCORE—takes
into account a combination of plasma biomarkers of ROS
production and antioxidant defense systems and has been
validated in several pathologies.11-13
The first aim of the present work was to quantify plasma
oxidative stress biomarkers that might be already changed
in patients at early stages of CVI (clinical classification as
CEAP C2) compared with healthy controls. With these
biomarkers, we have then calculated an oxidative stress
global index that could be used later for the development of
a diagnostic tool of CVI (OxyVen). To calculate the score,
we have included as suitable biomarkers those with the
following characteristics: (1) relevance of the parameter in
the ROS production or defense system, (2) discriminative
capacity between CVI patients and healthy controls, and
(3) feasibility of quantification with simple and high
throughput methods available in a routine clinical labora-
tory.
METHODS
The participants in this study were aware of the research
nature of the study and provided written informed consent.
The study was performed in accordance with the Declara-
tion of Helsinki, and the Hospital Human Research Com-
mittee approved the study protocol.
Materials
Polyvinylidene fluoride membrane was acquired from
Bio-Rad (Madrid, Spain) and a MemCode reversible pro-
tein stain kit from Pierce (Rockford, Ill). Antibody against
3-nitrotyrosine (3-NT) was purchased from Abcam (Ab-
cam, Cambridge, UK) and antimouse immunoglobulin G
peroxidase conjugated secondary antibody from DakoCy-
tomation (DakoCytomation, Glostrup, Denmark). The
rest of the chemicals were purchased from Sigma-Aldrich
(Madrid, Spain).
Participants
The study participants were patients undergoing vari-
cose vein surgery and healthy controls. All participants
underwent a physical examination, biochemical tests, and
color echo-Doppler assessment. They also answered a ques-
tionnaire regarding their health habits and drug consump-
tion or medication.
The control participants comprised 10 individuals (five
women, five men) who met the following criteria: (1) no
clinical signs of CVI and no signs of venous reflux deter-
mined by echo-Doppler (see below), (2) were free from all uiseases, (3) were not taking medications, (4) were non-
mokers, (5) had a body mass index25 kg/m2, (6) blood
ressure levels139/89 mmHg, (7) fasting glucose levels
110 mg/dL, and (8) cholesterol (total 200 mg/dL),
ow-density lipoprotein 160 mg/dL, and high-density
ipoprotein (40 mg/dL) within normal reference ranges.
The nine patients (five women, four men) included
ndividuals undergoing surgery who exhibited varicose
eins but no signs of edema, skin pigmentation, active or
ealed ulcerations, and were classified as CEAP C2. They
lso met the criteria of being nonsmokers, were free from
ther diseases except CVI, had weight and biochemical
arameters within normal reference ranges, andwere taking
o medications or drugs.
iagnosis of venous reflux
Echo-Doppler imaging was performed with a Toshiba
PLIO MX, lineal probe (7.4 to 10 MHz; Toshiba, Ma-
rid, Spain). The patient was standing, with the examined
eg in external rotation and leaning on the contralateral
eg. The Doppler assessment included examination of
he saphenous axis from the saphenofemoral junction to
he ankle and transverse and longitudinal sections of the
emoral vein. Saphenous vein diameter was measured
nd considered normal if 4 mm. The presence of reflux
long the different segments of the venous axis was
etermined by Valsalva maneuver and distal compres-
ion, and a reflux 0.5 seconds was considered patho-
ogic. An additional study of the external saphenous and
opliteal veins was performed on the back of the leg with
he patient standing on the contralateral leg. External
aphenous vein diameter 3 mm and perforating vein
iameter 3.5 mm were considered pathologic.
lood collection and plasma preparation
Blood (2.4 mL) was collected from each participant in
acutainer tubes (BD, Phymouth, UK) containing citrate
300 L). Blood samples were centrifuged at 900g for 10
inutes at 4°C to obtain plasma, which was aliquoted and
tored at 75 °C for further analysis.
iochemical tests
Total thiols. Plasma thiols were assessed by micro-
late 5,5´-dithiobis(2-nitrobenzoic acid) assay.14 The ab-
orbance was measured at 412 nm in a synergy high-
hroughput multimode analyzer (Bio-tek, Potton, UK),
nd thiol content was expressed as millimoles per liter of
educed glutathione (GSH) per milligram of protein.
Reduced glutathione. Plasma GSH was assessed by a
uorimetric micromethod based on the reaction with o-
hthalaldehyde.15,16 Fluorescence was measured in a Syn-
rgy HT multimode microplate reader (Synergy HT; Bio-
ek) at 360 40 nm excitation and 460 40 nm emission
avelengths, with a sensitivity of 75. The GSH level of the
amples was expressed as nanograms of GSH per milligram
f protein.
Uric acid. Plasma uric acid was assessed by Amplex red
ric acid/uricase assay (Amplex Ultra Red reagent; Invit-
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Volume 57, Number 1 Condezo-Hoyos et al 207rogen, Barcelona, Spain). Uric acid content was expressed
as mol/L.
Oxygen radical absorbance capacity-fluorescein as-
say. Plasma antioxidant capacity against peroxyl radicals
was assessed using the oxygen radical antioxidant capac-
ity-fluorescein (ORAC-FL) assay adapted to a conven-
tional microplate reader.17 The antioxidant capacity of
the plasma samples was expressed as the ORAC-FL
value: ORAC-FL valueDF [AUCsample – AUCblank]
[molarity of trolox]/[AUCtrolox – AUCblank] [liter of
plasma], where DF is the sample dilution factor,
AUCblank is the area under curve (AUC) in the presence
of 2,2’-azobis [2-methyl]propanimidamide dihydro-
chloride and in the absence of samples, and AUCtrolox is
the AUC in the presence of the standard antioxidant
trolox.
Total antioxidant capacity assay. Plasma antioxidant
capacity was assessed by total antioxidant capacity (TAC)
assay based on enhanced horseradish peroxidase-catalyzed
luminol chemiluminescence.18 The relative luminescence
(RL) was calculated as RL  [1 – luminescence (t)]/
[luminescence (t 0)]. This result was used to calculate the
AUC using GraphPad Prism software (GraphPad, San Di-
ego, Calif). TAC values were obtained from the standard
curve of the antioxidant trolox (1-4 mol/L), which was
calculated by regression analysis of the AUC vs trolox
concentration.
Protein-bound malondialdehyde. Plasma protein-
bound malondialdehyde (MDA) was assessed using thio-
barbituric acid assay.19 The protein-bound MDA level was
expressed in picomoles MDA per milligram of protein.
Total protein carbonyls. Plasma protein carbonyls
were assessed according 2,4-dinitrophenylhydrazine-based
assay.14 The protein carbonyl concentration was determined
using extinction coefficient of 2,4-dinitrophenylhydrazine
(ε  22,000/M cm) and expressed as nmol carbonyl per
milligram of protein.
Advanced oxidation protein products. The plasma
advanced oxidation protein products (AOPPs) level was
quantified by a spectroscopic method based on the oxida-
tion of iodide in acid by AOPPs.20 The level of AOPPs was
expressed as micromoles per liter of chloramine-T equiva-
lents per milligram of protein.
Total 3-NT. Plasma 3-NT was assessed by dot-blot
assay, as previously described.21
Catalase activity. Catalase activity was assessed by
Amplex red catalase assay (EnzChek Myeloperoxidase As-
say Kit with Amplex Ultra Red reagent; Invitrogen). Cata-
lase activity was expressed as units per milligram of protein.
Xanthine oxidase activity. Xanthine oxidase (XO)
activity was assessed by Amplex Red xanthine/XO assay
(EnzChek Myeloperoxidase Assay Kit with Amplex
UltraRed reagent; Invitrogen). XO activity was ex-
pressed as milliunits per milligram of protein.
Myeloperoxidase activity. Plasma myeloperoxidase
(MPO) activity was assessed by Amplex Red MPO assay
(EnzChek Myeloperoxidase Assay Kit with Amplex CltraRed reagent; Invitrogen). MPO activity was ex-
ressed as milliunits per milligram of protein.
Protein content. Protein content was assessed by
ig 1. Plasma antioxidant capacity. A, Fluorescence decay curves
nduced by the peroxyl radical generator 2,2=-azobis-2-methyl-
ropanimidamide dihydrochloride in the absence (white circles) and
he presence (black triangles) of plasma from patients with chronic
enous insufficiency and healthy controls. The inset shows oxygen
adical antioxidant capacity (ORAC) values.B,Variation in the lumi-
escence signal produced in Luminol-HRP-Hydrogen peroxide sys-
em before and after addition of plasma from patients with chronic
enous insufficiency or healthy controls. The inset figure shows total
ntioxidant capacity values. Data represent themean standard error
f the mean.oomassie blue–based microtiter plate assay according to
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was measured at 595 nm in a Synergy HT Multi-Mode
Microplate Reader (Bio-tek).
Calculation of OXyVen
These parameters were used to calculate a global index
of oxidative stress related to early stages of CVI, which we
called OXyVen. This index was calculated using the statis-
tical methodology previously described.13 Briefly, the steps
were:
1. Analysis of the normality of the chosen oxidative stress
biomarkers through the Kolmogorov-Smirnov test and
Q-Q graphs,
2. Normalization of the parameters that did not show a
normal distribution through a logarithmic transformation,
3. Parameter standardization, and
4. Calculation of the partial indexes for protein oxidative
damage (OXY) and antioxidant defense systems
(ANTIOX) and OXyVen according to the equation:
[OXyVenn Mean (ANTIOXik – OXYim)n] where: n
is the experimental group, i is the individual, k are the
parameters related to ANTIOX, andm are the param-
Fig 2. Plasma antioxidant defense systems: (A) total th
catalase activity in patients with chronic venous insufficien
error of the mean. **P  .001 vs control subjects.eters related to OXY biomarkers. rtatistical analysis
GraphPad Prism software was used for lineal regres-
ion analysis and Student t test. The normality of param-
ters and normalization procedure were performed using
PSS 19 software (IBM Corp, Armonk, NY).
ESULTS
Patients were aged 25 to 51 years, and participants were
ged 24 to 45 years and had no signs of venous disease.
Echo-Doppler results. The echo-Doppler showed
hat all patients exhibited only superficial great saphe-
ous vein reflux, without deep or perforator disease.
here were no differences related to age between pa-
ients and controls.
Plasma antioxidant defense systems. TheORAC-FL
ssay showed that in the absence of plasma, there was a
radual fluorescence decay of fluorescein in time, totally
ost after 50 minutes. The addition of plasma from patients
r controls retarded the fluorescence decay to a similar
xtent, with no significant difference in ORAC values be-
ween groups (Fig 1, A, inset). This result was confirmed
sing the TAC method, showing a similar luminescence
ntent, (B) reduced glutathione, (C) uric acid, and (D)
d healthy controls. Data represent the mean standardiols co
cy anecovery with plasma from patients and controls (Fig 1, B)
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(Fig 1, B, inset).
Total plasma thiols were significantly decreased in
the patient group (Fig 2, A). However, there was no
statistical difference in GSH levels, despite a tendency to
be reduced in patients (Fig 2, B). It was not possible to
measure oxidized glutathione due to the very low levels
in plasma (2%).22 Uric acid levels were also similar in
healthy controls and patients (Fig 2, C). Plasma catalase
activity was significantly lower in patients, being approx-
imately one-third of the control group (Fig 2, D).
Oxidative damage to proteins. Levels of total protein-
bound MDA and plasma carbonyls were significantly
larger in plasma from patients with CVI, being approxi-
mately double compared with values for healthy controls
(Fig 3, A and B). However, plasma 3-NT and AOPPs
were not statistically different between groups (Fig 3, C
Fig 3. Parameters related to protein oxidative damage
carbonyls, (C) 3-nitrotyrosine (3-NT), and (D) advance
chronic venous insufficiency and healthy controls. Data r
with respect to control.and D). OActivity of enzymatic systems related to ROS
roduction. MPO and XO activities were not statistically
ifferent in plasma from patients compared with control
articipants (Fig 4).
Analysis of partial and global oxidative stress-
elated indexes. The OXyVen was calculated from the
ormalized and standardized plasma parameters, which
howed a significant statistical difference between study
roups: total thiols, catalase activity, protein-bound MDA,
nd protein carbonyls. Catalase activity and protein-bound
DA did not exhibit a normal distribution and were nor-
alized by a logarithmic transformation before standard-
zation. The Table reports the standardized and normalized
arameters for each individual included in the study and the
alculated partial indexes, ANTIOX (antioxidant defense sys-
ems), OXY (protein oxidative damage), and OXyVen. There
as a significant statistical difference in ANTIOX, OXY, and
protein-bound malondialdehyde (MDA), (B) protein
dation products measured in plasma from patients with
ent the mean standard error of the mean. **P .001: (A)
d oxi
epresXyVen between patients and control participants.
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January 2013210 Condezo-Hoyos et alThe control group exhibited an OXyVen value of
nearly 0, which means there is a balance between antioxi-
dant defense systems and oxidative damage of the individ-
ual. Therefore, the larger the deviation from these control
values—in absolute terms—the greater the global oxidative
damage in the individual.
DISCUSSION
There is evidence of elevated ROS in CVI, produced by
infiltrated or circulating inflammatory cells as well as by the
varicose vein wall itself.5-7 Recent work has demonstrated
that the degree of oxidative damage may correlate with the
Fig 4. Activity of enzymes related to reactive oxygen species
(ROS) production: (A) myeloperoxidase (MPO) and (B) xanthine
oxidase activities in plasma from patients with chronic venous
insufficiency and healthy controls. Data represent the mean 
standard error of the mean. MPO, Myeloperoxidase.clinical degree of venous disease.23 However, whether the tVI-associated oxidative stress can be measured in plasma
s not clear. Plasma is considered a good biologic fluid to
etermine the oxidative stress status in a disease,24 and the
ack of consensus regarding CVI8,9,25 is probably because
revious studies have focused on single oxidative stress-
elated biomarkers that might have a large intraindividual
nd interindividual variability or that are not representative
f CVI. Therefore, measuring several parameters to have a
epresentative global measurement of ROS production and
amage, as well as antioxidant defense systems, would be
esirable.
Taking into account these requirements, a global index
f plasma oxidative stress has been recently developed and
alidated in several diseases and in aging.11-13 Therefore,
he aim of the present study was to develop the OXyVen, a
imilar global index specific for CVI, which could reflect the
lasma oxidative stress status in early stages of the disease.
or this reason, we included only patients classified as
EAP C2 and compared them with healthy individuals
ith no sign of venous pathology, confirmed by an echo-
oppler assessment.
Oxidative stress is related to cardiovascular diseases and
isk factors, such as diabetes, hypertension, and obesity,
hich are very prevalent in the population.26 Many oxida-
ive stress parameters are relevant in cardiovascular pathol-
gies and could, in principle, be altered in CVI. In the
resent study, we chose those that have been previously
ound altered in the wall of varicose veins and that can be
easured in plasma with simple and high-throughput
ethods adaptable to routine clinical laboratory analysis.
Parameters related to antioxidant capacity. We did
ot find differences in ORAC-FL and TAC values, assays
hat detect nonenzymatic low-molecular-weight antioxi-
ant compounds, such as uric acid and GSH.18,27 Similar
esults have been recently reported, assaying antioxidant
apacity against peroxyl radical with 2,2=-azino-bis(3-
thylbenzothiazoline-6-sulphonic acid) cation radical as
robe.25 In agreement with these results, uric acid or GSH
id not show differences between patients and controls.
ric acid is the predominant molecule, representing70%
f plasma low-molecular-weight antioxidants,27 and GSH
s a key reducing agent participating as a ROS scavenger and
s a cofactor of several antioxidant enzymatic systems.22A
ecent study reported that uric acid content is decreased in
EAP C2 patients. However, since these authors did not
eport a change in antioxidant capacity, they suggest that
ther reducing compounds might also be involved.25 This
ossibility is confirmed by the present study, demonstrating
reduction in C2 patients of total thiols related to cys-
roteins.
Regarding enzymatic systems responsible for ROS re-
oval, catalase is a key enzyme responsible for the catabo-
ism of hydrogen peroxide, which is the end ROS product
enerated by dismutation of the superoxide radical in phys-
ologic conditions. The catabolic role of this enzyme is
estricted to exogenous hydrogen peroxide,28 which can be
ecreted in large amounts by inflammatory cells,29 known
o be key for the pathologic process in the varicose vein
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Volume 57, Number 1 Condezo-Hoyos et al 211wall.30–33 Catalase activity was reduced in patients, and we
suggest that this might be the result of damage by ROS, for
example, by peroxynitrite, as previously demonstrated.34
Peroxynitrite, the product of nitric oxide (NO) and super-
oxide anion, could be elevated in CVI because varicose
veins produce high amounts of superoxide anion through
nicotinamide adenine dinucleotide phosphate hydrogen
(NADPH) oxidases.35
Parameters of ROS damage and production. Lipid
peroxides have been suggested to play a role in the oxida-
tive damage in CVI, for example, after thrombophlebitis,5
and in damaged valves in advanced stages of CVI.7 To
determine lipid peroxide-induced damage to plasma pro-
teins, we quantified MDA, an aldehyde produced in large
amounts during lipid peroxidation by ROS. Our results
show that in earlier stages of CVI (C2), plasma MDA levels
are already increased, as recently described in plasma25 and
in homogenates from varicose and insufficient veins com-
pared with healthy tissue.23 Our data are in contrast to the
studies of Yassim et al,9 which did not find such differences,
likely because they measured free MDA, whereas we mea-
sured the conjugated form, which is the predominant form
in plasma. Accordingly, we found that plasma protein
carbonyls—also related to oxidative damage induced by
lipid peroxidation36—were higher in plasma from patients
with varicose veins (C2). These data suggest that lipid
peroxidation might be an early event in venous pathology.
The main vascular enzymatic systems responsible for
ROS production are NADPH oxidase, uncoupled NO
Table. Individual standardized parameters and the indexe
insufficiency and controls
Group
Standardized variables
Log catalase
activity
Protein
carbonyls
Log protein-bound
MDA
Controls (n  10) 1.309 0.304 1.444
1.134 1.466 0.324
0.727 0.238 1.561
0.204 1.023 1.267
1.890 0.404 0.206
0.669 0.149 0.088
0.204 1.919 0.913
0.785 1.023 0.619
0.669 0.857 1.208
0.553 0.083 0.206
Patients (n  9) 2.123 4.319 2.386
2.673 4.175 2.033
1.250 2.173 1.090
2.007 8.268 0.088
1.832 5.281 1.326
1.948 4.728 1.620
2.763 8.732 1.915
1.716 3.091 2.799
1.658 2.848 1.797
ANTIOX, Antioxidant defense systems;MDA,malondialdehyde; OXY, pro
inssuficiency.
aIndex values are expressed as mean (standard error of the mean).
bP  .0001 respect to controls.synthase (NOS), XO, and MPO.5,35 MPO and XO activi- iies are altered in varicose vein pathology.5,37 MPO was
nchanged in plasma from patients at C2 stages of CVI,
hich suggests that this enzyme requires higher levels of
eukocyte activation such as those described in patients at
3 or C4 stages.
38 These data, together with the lack of
ncrease in plasma AOPPs,20 which are generated by hypo-
hlorous acid, the product of MPO, suggest that this
nzyme is not activated in the early stages of CVI and
herefore is not a good biomarker at these stages of the
isease.
XO is another enzymatic system that is elevated in
enous pathology in response to hypoxia.35 We found no
ifferences in the activity of this enzyme in the plasma from
ur patients at C2. This might have two explanations:
xpression is increased but not activity, or this enzyme is
ot secreted to the plasma in sufficient quantities in the
arly stages of CVI. In any case, these results suggest that
O is not a suitable biomarker in early stages of the pathol-
gy.
We found increased oxidative damage to plasma pro-
eins but did not detect modifications in XO and MPO.
herefore, there must be another source of ROS produc-
ion in our samples. NADPH oxidase is another important
nzyme associated with oxidative stress in the vascular wall
hat, together with uncoupledNOS, is increased in varicose
eins.35 We were not able to measure the activity of these
wo enzymes because they are membrane-bound proteins
nd are not released to the plasma. On the basis of these
ata, we suggest that the plasma protein oxidative damage
ulated from them in patients with chronic venous
Indexa
al thiols ANTIOX OXY OXyVen
0.532
1.482
0.053
0.587
1.838 0.000 (0.570) 0.000 (0.407) 0.000 (0.548)
0.028
0.998
0.863
0.606
0.828
0.733
0.789
1.099
1.420 2.996b (0.841) 6.499b (0.203) 9.495b (0.692)
1.856
0.087
0.952
1.173
0.884
xidative damage; OXyVen,Oxidative Stress Global Index of chronic venouss calc
Tot
















tein on patients with CVI comes mainly from NADPH oxidase
R1
1
1
1
1
1
1
1
1
1
2
2
2
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tance of these two enzymatic systems in the varicose vein,35
they are not suitable plasma biomarkers of CVI.
The OXyVen. Oxidative stress is a complex problem
that is the consequence of unbalanced ROS production and
destruction, where many biomarkers play a role. Therefore,
to describe the oxidative status in an individual, a global
score is required that includes the most relevant parameters
of the pathology under study.13 Therefore, we considered
it appropriate to apply this concept to develop theOXyVen,
global index of the early stages of CVI. This score exhibited
a highly significant difference in plasma from patients com-
pared with the healthy control group, suggesting that the
alterations of redox status associated with varicose vein
pathology are already detectable in plasma at early stages
of CVI.
Study limitations. We have described for the first
time, to our knowledge, the calculation of a global index of
oxidative status of an individual that allows differences to be
detected at early stages of CVI. We propose that this index
can be used as a diagnostic tool for early detection of CVI
or its progression. Obviously, this requires further develop-
ment and studies, including a larger number of individuals,
which is a limitation of this study; for example, inclusion of
patients at C1 stages of CVI, which do not exhibit varicose
veins, and to monitor them in a longitudinal study to
establish if an initial elevation of oxidative stress can predict
CVI progression.
CONCLUSIONS
Although CVI is not a life-threatening condition, it is
relatively common, particularly in some risk groups, and
surgery is the treatment of choice. Therefore, an early
detection in groups at risk and the development of preven-
tive treatments with antioxidant-related pharmacologic
therapy could reduce the number of surgical interventions
with all the inconveniences and costs implicated. Another
possible application of this tool could be to predict the
progression of the disease; for example, screening patients
undergoing surgery and assessing the possible relationship
between initial oxidative status and the development of
recurrence.
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